Rubedo Life Sciences
rubedolife.com
Actively hiring
Health Care
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$40M
1 round on record
Latest round
$40M
Venture round · Apr 2024 · 2 yr ago
Backers
2
CDP Venture Capital, Italian Angels for Growth
The money's age
Long since its last round
29 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 22, 2024
Raised a round Venture round $40M · Pulse 2.0
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Apr 2024 | $40M | — | Pulse 2.0 |
Backed byfrom the funds' portfolios and accelerator catalogs
CDP Venture Capital 
Italian Angels for Growth Similar startupsby what they do, their industry and backers
Tattva - Creating a world where buildings are biologically grown.
Cellply offers an automated platform for functional precision medicine.
Discover WeMaintain’s innovative building maintenance solutions in Singapore. Expert services for lifts, escalators, fire safety, and more…
The premier provider of Sovereign Cloud & Managed Services Cloud Carib is the premier provider of trusted cloud services in the Caribbean…
Pioneering a New Era of Precision Medicines to Restore Brain Health and Wellbeing.
Discover how Day One Biopharmaceuticals is disrupting the status quo of traditional drug development to bring new medicines to children and…
News
Rubedo Life Sciences宣布将开展GPX4调节剂RLS-1496治疗脱发的临床研究首个人体离体研究证据显示其可有力促进毛囊生长_腾讯新闻
雄激素性脱发AGA临床试验将于2026年秋季启动由David Pariser医学博士美国医师学会会士、美国皮肤病学会会士牵头David Pariser曾任美国皮肤病学会会长并担任过450余项皮肤病临床试验的主要研究者 Rubedo旗下RLS-1496是目前首个且唯一进入临床试验的GPX4调节剂在人体离体雄激素性脱发AGA模型中展现...
Read more
Report
Rubedo Life Sciences anuncia un estudio clínico para tratar la caída del cabello con el modulador de GPX4 RLS-1496; los primeros datos ex vivo en humanos muestran un marcado crecimiento de los folículos pilosos
MOUNTAIN VIEW, California, September 16, 2026--Rubedo Life Sciences, Inc. (Rubedo) anunció hoy un nuevo estudio clínico de RLS-1496, un tratamiento en investigación para pacientes con AGA, que comenzará en octubre de 2026 y cuyos primeros datos se esperan
Read more
Report
Rubedo Life Sciences宣布啟動GPX4調節劑RLS-1496治療脫髮的臨床試驗首批人體體外證據證實可顯著促進毛囊生長
加州山景城, September 16, 2026--(美國商業資訊)--Rubedo Life Sciences, Inc. (Rubedo)今日宣布將於2026年10月啟動一項針對雄性遺傳性脫髮(AGA)病患的試驗中藥物RLS-1496的新臨床研究初步資料可望於2027年上半年公布該研究代表GPX4調節劑在脫髮治療中的首次臨床評估進一步擴大了RLS-1496的研發計畫使其成為全球首款進入人體臨床試驗的GPX4調節劑
Read more
Report
A Rubedo Life Sciences anuncia estudo clínico para tratar a perda de cabelo com o modulador de GPX4 RLS-1496; primeira evidência humana "ex vivo" demonstra crescimento robusto do folículo piloso
Ensaio clínico para alopecia androgenética (AGA) terá início no outono de 2026, liderado pelo Dr. David Pariser (MD, FACP, FAAD), ex-presidente da Academia Americana de Dermatologia e investigador principal em mais de 450 ensaios clínicos de dermatologiaO
Read more
Report
Pro access
Upgrade to see all 14 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.
Financials
Total raised
$40M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2024 | $40M | Details |